Comments on: Life sciences briefing: Friday, Sept. 21, 2007 http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/ News About Tech, Money and Innovation Wed, 25 Nov 2009 08:36:57 +0000 http://wordpress.org/?v=2.8.5 hourly 1 By: VentureBeat » Life sciences briefing: Monday, Oct. 8, 2007 http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/comment-page-1/#comment-569592 VentureBeat » Life sciences briefing: Monday, Oct. 8, 2007 Tue, 09 Oct 2007 08:53:36 +0000 http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/#comment-569592 [...] Zars reportedly postponed an IPO that had been scheduled for that week. (See our previous coverage here, here and [...] [...] Zars reportedly postponed an IPO that had been scheduled for that week. (See our previous coverage here, here and [...]

]]> By: VentureBeat » IPO roundup: MAP Pharma’s mixed reception, other recent filings http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/comment-page-1/#comment-568304 VentureBeat » IPO roundup: MAP Pharma’s mixed reception, other recent filings Mon, 08 Oct 2007 16:21:39 +0000 http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/#comment-568304 [...] drug budesonide, which is used to treat pediatric asthma. See our previous coverage of the company here (second item) and [...] [...] drug budesonide, which is used to treat pediatric asthma. See our previous coverage of the company here (second item) and [...]

]]> By: VentureBeat » Complete Genomics and BioNanomatrix rev up the fast, cheap and out-of-control genome race http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/comment-page-1/#comment-559176 VentureBeat » Complete Genomics and BioNanomatrix rev up the fast, cheap and out-of-control genome race Mon, 01 Oct 2007 18:15:02 +0000 http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/#comment-559176 [...] Things are starting to get crowded in the race to sequence entire human genomes quickly and relatively cheaply — usually meaning somewhere in the territory of $1,000 per genome, compared to the $100,000+ it costs with current technology. At least four startups have taken on the $1,000 genome challenge, two of which have already been acquired by larger companies. (See details at the end of the first item here.) [...] [...] Things are starting to get crowded in the race to sequence entire human genomes quickly and relatively cheaply — usually meaning somewhere in the territory of $1,000 per genome, compared to the $100,000+ it costs with current technology. At least four startups have taken on the $1,000 genome challenge, two of which have already been acquired by larger companies. (See details at the end of the first item here.) [...]

]]> By: VentureBeat » Complete Genomics and BioNanomatrix rev up the fast, cheap and out-of-control genome race http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/comment-page-1/#comment-559190 VentureBeat » Complete Genomics and BioNanomatrix rev up the fast, cheap and out-of-control genome race Mon, 01 Oct 2007 18:15:02 +0000 http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/#comment-559190 [...] Things are starting to get crowded in the race to sequence entire human genomes quickly and relatively cheaply — usually meaning somewhere in the territory of $1,000 per genome, compared to the $100,000+ it costs with current technology. At least four startups have taken on the $1,000 genome challenge, two of which have already been acquired by larger companies. (See details at the end of the first item here.) [...] [...] Things are starting to get crowded in the race to sequence entire human genomes quickly and relatively cheaply — usually meaning somewhere in the territory of $1,000 per genome, compared to the $100,000+ it costs with current technology. At least four startups have taken on the $1,000 genome challenge, two of which have already been acquired by larger companies. (See details at the end of the first item here.) [...]

]]> By: VentureBeat » Vascular Architects sold for a pittance http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/comment-page-1/#comment-546128 VentureBeat » Vascular Architects sold for a pittance Fri, 21 Sep 2007 18:22:55 +0000 http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/#comment-546128 [...] medical-device maker, which raised over $42 million but just sold itself for $2.8 million, in today’s daily briefing at VentureBeat Life Sciences. Tagged N/A VentureBeat [...] [...] medical-device maker, which raised over $42 million but just sold itself for $2.8 million, in today’s daily briefing at VentureBeat Life Sciences. Tagged N/A VentureBeat [...]

]]> By: VentureBeat » Vascular Architects sold for a pittance http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/comment-page-1/#comment-546142 VentureBeat » Vascular Architects sold for a pittance Fri, 21 Sep 2007 18:22:55 +0000 http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/#comment-546142 [...] medical-device maker, which raised over $42 million but just sold itself for $2.8 million, in today’s daily briefing at VentureBeat Life Sciences. Tagged N/A VentureBeat [...] [...] medical-device maker, which raised over $42 million but just sold itself for $2.8 million, in today’s daily briefing at VentureBeat Life Sciences. Tagged N/A VentureBeat [...]

]]> By: VentureBeat » MAP Pharma prices IPO, aims for $92M haul http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/comment-page-1/#comment-546114 VentureBeat » MAP Pharma prices IPO, aims for $92M haul Fri, 21 Sep 2007 18:21:05 +0000 http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/#comment-546114 [...] our story on this Mountain View, Calif., specialty-pharmaceutical company in today’s daily briefing at VentureBeat Life Sciences. Tagged N/A VentureBeat [...] [...] our story on this Mountain View, Calif., specialty-pharmaceutical company in today’s daily briefing at VentureBeat Life Sciences. Tagged N/A VentureBeat [...]

]]> By: VentureBeat » Complete Genomics raises second round for high-speed sequencing http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/comment-page-1/#comment-546086 VentureBeat » Complete Genomics raises second round for high-speed sequencing Fri, 21 Sep 2007 18:19:00 +0000 http://venturebeat.com/2007/09/21/life-sciences-briefing-friday-sept-21-2007/#comment-546086 [...] our story on this Mountain View, Calif., biotech in today’s daily briefing at VentureBeat Life Sciences. Tagged co:Complete Genomics VentureBeat [...] [...] our story on this Mountain View, Calif., biotech in today’s daily briefing at VentureBeat Life Sciences. Tagged co:Complete Genomics VentureBeat [...]

]]>